This activity is expired and is no longer available for CME credit.


Rheumatic Complications of Cancer Immunotherapy: A New and Emerging Field in Rheumatology

Author(s)/Faculty: Leonard H. Calabrese, DO; Jan Leipe, MD; Xavier Mariette, MD, PhD
Release Date: 8/14/2018Expiration Date: 4/8/2021
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
The introduction of immune checkpoint inhibitors has had a great impact on the field of oncology. However, these new therapies are associated with a spectrum of autoimmune and systemic inflammatory reactions known as immune-related adverse events (irAEs). Rheumatologists are likely to encounter a wide variety of irAEs as the use of immune checkpoint inhibitors expands in the treatment of several cancers. Thus, it is critical for rheumatologists to be aware of these complications to accurately diagnose and manage the toxicities of immune checkpoint inhibitors in collaboration with treating oncologists. In this CME activity, expert faculty will review the role of the immune system in tumor biology and the appropriate management of rheumatic irAEs associated with immune checkpoint inhibitors. Case-based example will illustrate best practices for recognizing and managing these adverse events.